Luxembourg, 17/12/2020

Public

Environmental and Social Data Sheet

Overview

Project Name:	OSE IMMUNOTHERAPEUTICS (EGFF)
Project Number:	2019-0866
Country:	France
Project Description:	The project concerns RDI investments in the Company's proprietary platform of innovative therapies for immuno-oncology and autoimmune diseases. The Company's pipeline includes an immunotherapy that is in Phase III clinical stage for the treatment of lung cancer, as well as in Phase II clinical trial to pancreatic cancer, a humanized monoclonal antibody that is in preclinical stage for the treatment of various cancers, a humanized monoclonal antibody that is in Phase I clinical trial for the treatment of inflammatory autoimmune diseases and a prophylactic vaccine against SARS-CoV-2, for which the clinical phase start is expected in Q1-2021.

EIA required: no

Project included in Carbon Footprint Exercise[1]: no

(details for projects included are provided in section: “EIB Carbon Footprint Exercise”)

Environmental and Social Assessment

Environmental Assessment

- *The Promoter’s investments that will be financed through this operation concern research, development and innovation activities carried out in the pharmaceutical sector, enabling the Company to develop its lead development assets, Tedopi, FR104, OSE 230, and CoVepiT in different disease areas associated with high medical needs (eg. COVID-19 prevention). The project activities are not listed in any of the annexes of the EU Directive 2014/52/EU amending 2011/92/EU.*
- *Furthermore, the project will be carried out in existing facilities already authorised for similar activities and volumes. Therefore, an Environmental Impact Assessment (EIA) is not required.*
- *The promoter’s R&D facilities and practices are compliant with relevant national and EU regulations and the promoter maintains adequate internal procedures and management practices. The use of animal testing is minimised and in line with the EU Directive 2010/63/EU. In addition, The Company has adequate policies and procedures in place to outsource and manage clinical trials in the different regions of the world in accordance with the EU 536/2014 regulation. The clinical trials, which are sponsored by the project, are performed under regulated and strictly controlled*

[1] Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO2e/year absolute (gross) or 20,000 tonnes CO2e/year relative (net) – both increases and savings.

conditions, in existing specialised facilities, which are regularly inspected by competent authorities - EMA in Europe and/or national equivalent bodies in the rest of the world (e.g. FDA).

Social Assessment, where applicable

If successful, the project is expected to lead to important social benefits stemming from its focus on the development of novel treatments and prevention methods for diseases associated with substantial social and economic impact such as COVID-19.

Conclusions and Recommendations

The project while contributing to the EU coordinated response to the COVID-19 crisis, will not result in any significant additional negative environmental and social impacts. It is therefore considered acceptable for the Bank financing in environmental and social terms.